B7-H3 Antibody (G-12): sc-398403
- B7-H3 Antibody (G-12) is a mouse monoclonal IgG1 κ, cited in 1 publications, provided at 200 µg/ml
- specific for an epitope mapping between amino acids 82-107 near the N-terminus of B7-H3 of human origin
- recommended for detection of B7-H3 of mouse, rat and human origin by WB, IP, IF and ELISA; also reactive with additional species, including and canine and bovine
- m-IgG Fc BP-HRP, m-IgG1 BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for B7-H3 Antibody (G-12) for WB applications. These reagents are now offered in bundles with B7-H3 Antibody (G-12) (see ordering information below).
QUICK LINKS
SEE ALSO...
B7-H3 Antibody (G-12) is a mouse monoclonal IgG1 antibody that detects B7-H3 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). B7-H3, also known as B7-homolog 3 or B7RP-2, is a member of the B7 Immunoglobulin superfamily and plays a crucial role in the regulation of T cell activation and immune responses. B7-H3 is widely expressed in non-lymphoid tissues, where B7-H3 serves as a costimulatory molecule that enhances the proliferation of both CD4+ and CD8+ T cells. Notably, B7-H3 has been shown to stimulate T helper 1 and cytotoxic T cell responses, suggesting potential antitumor activity. B7-H3 interactions with receptors may be pivotal in modulating cell-mediated immune responses against tumors, positioning B7-H3 as a promising target for therapeutic interventions in cancer treatment. With versatile applications and significant role in immune regulation, anti-B7-H3 antibody (G-12) is an essential tool for researchers exploring the complexities of immune responses and cancer biology.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
B7-H3 Antibody (G-12) References:
- Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature. | Seaman, S., et al. 2017. Cancer Cell. 31: 501-515.e8. PMID: 28399408
- B7-H3 in Cancer - Beyond Immune Regulation. | Flem-Karlsen, K., et al. 2018. Trends Cancer. 4: 401-404. PMID: 29860983
- B7-H3-targeted Radioimmunotherapy of Human Cancer. | Kasten, BB., et al. 2020. Curr Med Chem. 27: 4016-4038. PMID: 30836909
- B7-H3 Immune Checkpoint Protein in Human Cancer. | Flem-Karlsen, K., et al. 2020. Curr Med Chem. 27: 4062-4086. PMID: 31099317
- B7-H3: A promising therapeutic target for autoimmune diseases. | Chen, Y., et al. 2020. Cell Immunol. 352: 104077. PMID: 32113615
- B7-H3, a checkpoint molecule, as a target for cancer immunotherapy. | Yang, S., et al. 2020. Int J Biol Sci. 16: 1767-1773. PMID: 32398947
- Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors. | Yang, M., et al. 2020. Theranostics. 10: 7622-7634. PMID: 32685008
- The role of B7-H3 in tumors and its potential in clinical application. | Feng, R., et al. 2021. Int Immunopharmacol. 101: 108153. PMID: 34678689
- FDW028, a novel FUT8 inhibitor, impels lysosomal proteolysis of B7-H3 via chaperone-mediated autophagy pathway and exhibits potent efficacy against metastatic colorectal cancer. | Wang, M., et al. 2023. Cell Death Dis. 14: 495. PMID: 37537172
- Soluble B7-H3 in Colorectal Cancer. | Kovaleva, OV., et al. 2023. Bull Exp Biol Med. 176: 87-90. PMID: 38085395
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
B7-H3 Antibody (G-12) | sc-398403 | 200 µg/ml | $322.00 | |||
B7-H3 Antibody (G-12): m-IgG Fc BP-HRP Bundle | sc-538436 | 200 µg Ab; 10 µg BP | $361.00 | |||
B7-H3 Antibody (G-12): m-IgGκ BP-HRP Bundle | sc-536049 | 200 µg Ab; 40 µg BP | $361.00 | |||
B7-H3 Antibody (G-12): m-IgG1 BP-HRP Bundle | sc-545701 | 200 µg Ab; 20 µg BP | $361.00 | |||
B7-H3 (G-12) Neutralizing Peptide | sc-398403 P | 100 µg/0.5 ml | $69.00 |